TY - JOUR T1 - OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease JF - medRxiv DO - 10.1101/2019.12.13.19014902 SP - 2019.12.13.19014902 AU - Pamela J. LaMontagne AU - Tammie LS. Benzinger AU - John C. Morris AU - Sarah Keefe AU - Russ Hornbeck AU - Chengjie Xiong AU - Elizabeth Grant AU - Jason Hassenstab AU - Krista Moulder AU - Andrei G. Vlassenko AU - Marcus E. Raichle AU - Carlos Cruchaga AU - Daniel Marcus Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/15/2019.12.13.19014902.abstract N2 - OASIS-3 is a compilation of MRI and PET imaging and related clinical data for 1098 participants who were collected across several ongoing studies in the Washington University Knight Alzheimer Disease Research Center over the course of 15 years. Participants include 605 cognitively normal adults and 493 individuals at various stages of cognitive decline ranging in age from 42 to 95 years. The OASIS-3 dataset contains over 2000 MR sessions, including multiple structural and functional sequences. PET metabolic and amyloid imaging includes over 1500 raw imaging scans and the accompanying post-processed files from the PET Unified Pipeline (PUP) are also available in OASIS-3. OASIS-3 also contains post-processed imaging data such as volumetric segmentations and PET analyses. Imaging data is accompanied by dementia and APOE status and longitudinal clinical and cognitive outcomes. OASIS-3 is available as an open access data set to the scientific community to answer questions related to healthy aging and dementia.Competing Interest StatementAuthors P.J.L., S.K., R.H., E.G., C.X., J.H., K.M., A.G.V., M.E.R., C.C. declare no competing interests. J.C.M. is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and UF1AG032438. Neither J.C.M. nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. T.L.S.B. Participated in clinical trials sponsored by Eli Lilly, Roche, and Biogen. Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) provided T.L.S.B. doses of 18F-florbetapir, partial funding for 18F-florbetapir scanning, precursor for 18F-flortaucipir and technology transfer for manufacturing of 18F-flortaucipir).Funding StatementFunding for the Knight ADRC and KARI were provided by NIH P50AG00561, P30NS09857781, P01AG026276, P01AG003991, R01AG043434, R01AG054567, UL1TR000448, and R01EB009352. Florbetapir doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOASIS-3 data is openly available to the scientific community at https://www.oasis-brains.org. Prior to accessing the data, users are required to agree to the OASIS Data Use Terms. http://www.oasis-brains.org/ ADAlzheimer DiseaseADRCAlzheimer Disease Research CenterAPOEASLarterial spin labelingAV45Florbetapir (18F-AV-45)BPNDbinding potentialCDRClinical Dementia RatingCSFcerebrospinal fluidDWIdiffusion weighted imagingDATis outmoded; use “AD dementia” or “symptomatic AD” – the latter term can be stated to encompass both MCI due to AD and AD dementiaFDGfluorodeoxyglucose (18F-FDG)BOLDblood oxygen level dependentMCBPmean cortical binding potentialmCimillicurieMCSUVRmean cortical SUVRMRImagnetic resonance imagingOASISOpen Access Series of Imaging StudiesPiBPittsburgh compound B (11C-PIB)PUPPet Unified PipelinePETPositron emission tomographyPVEpartial volume effectsQCquality controlrsfregional spread functionSWIsusceptibility weighted imagingSUVRstandard uptake ratioTOFtime of flightUDSUniform Data Set ER -